<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295785</url>
  </required_header>
  <id_info>
    <org_study_id>2019PI192</org_study_id>
    <nct_id>NCT04295785</nct_id>
  </id_info>
  <brief_title>Juvenile Autoimmune Necrotizing Myopathies</brief_title>
  <acronym>MYONECPED</acronym>
  <official_title>Clinical, Paraclinical, Functional Characteristics and Evolution of Juvenile Autoimmune Necrotizing Myopathies in a National Retrospective Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune necrotizing myopathies (AINM) in adult patients are characterized by severity of
      muscle damage, presence of necrosis with little inflammation on muscle biopsy and anti-HMGCR
      or anti-SRP auto-antibodies. Data on AINM in children are currently lacking. The purpose of
      this study is to specify the characteristics at AINM diagnosis, treatments and evolution of
      juvenile AINM with anti-HMGCR or anti-SRP antibodies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Type of muscle involvment</measure>
    <time_frame>At diagnosis</time_frame>
    <description>Proximal or distal or axial muscle involvement by muscle testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of cutaneous involvment</measure>
    <time_frame>At diagnosis</time_frame>
    <description>Rash or Gottron lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Other clinical manifestations</measure>
    <time_frame>At diagnosis</time_frame>
    <description>Dysphagia or dyspnea or fever or interstitial lung involvement or articular involvement or gastrointestinal involvment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood CK level</measure>
    <time_frame>At diagnosis</time_frame>
    <description>Blood CK level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histology</measure>
    <time_frame>At diagnosis</time_frame>
    <description>Results of muscle biopsy : necrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histology</measure>
    <time_frame>At diagnosis</time_frame>
    <description>Results of muscle biopsy : inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MMT score</measure>
    <time_frame>At diagnosis</time_frame>
    <description>MMT score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CMAS score</measure>
    <time_frame>At diagnosis</time_frame>
    <description>CMAS score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of drugs used</measure>
    <time_frame>At last visit</time_frame>
    <description>Drugs ever used : name and duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iatrogenic complications</measure>
    <time_frame>At last visit</time_frame>
    <description>Infectious complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iatrogenic complications</measure>
    <time_frame>At last visit</time_frame>
    <description>Bone complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of the disease at last visit</measure>
    <time_frame>At last visit</time_frame>
    <description>Status of the disease at last visit : active or remission or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses</measure>
    <time_frame>At last visit</time_frame>
    <description>Number of relapses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of muscle involvment</measure>
    <time_frame>At last visit</time_frame>
    <description>Proximal or distal or axial muscle involvement by muscle testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of cutaneous involvment</measure>
    <time_frame>At last visit</time_frame>
    <description>Rash or Gottron lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clinical manifestations</measure>
    <time_frame>At last visit</time_frame>
    <description>Dysphagia or dyspnea or fever or interstitial lung involvement or articular involvement or gastrointestinal involvment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood CK level</measure>
    <time_frame>At last visit</time_frame>
    <description>Blood CK level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMAS score</measure>
    <time_frame>At last visit</time_frame>
    <description>CMAS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMT score</measure>
    <time_frame>At last visit</time_frame>
    <description>MMT score</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Immune-Mediated Necrotizing Myopathy</condition>
  <arm_group>
    <arm_group_label>autoimmune necrotizing myopathy beginning before 18</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        AINM histologically proved (i.e. predominant muscle fibers necrosis lesions associated with
        minimal or absent inflammatory lesions), either anti-SRP or anti-HMGCR antibodies
        positivity and a disease onset before age 18
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AINM histologically proved by predominant muscle fibers necrosis lesions associated
             with minimal or absent inflammatory lesions

          -  Either anti-SRP or anti-HMGCR antibodies positivity

          -  Disease onset before age 18

        Exclusion Criteria:

          -  Seronegative necrotizing myopathies

          -  Forms compatible with another type of myositis (e.g. dermatomyositis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Irène LEMELLE</last_name>
    <phone>03 83 15 45 96</phone>
    <email>i.lemelle@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital d'enfants CHRU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54 500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol. 2016 Oct;29(5):662-73. doi: 10.1097/WCO.0000000000000376. Review.</citation>
    <PMID>27538058</PMID>
  </reference>
  <reference>
    <citation>Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurol. 2018 Dec 1;75(12):1528-1537. doi: 10.1001/jamaneurol.2018.2598.</citation>
    <PMID>30208379</PMID>
  </reference>
  <reference>
    <citation>Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, Suzuki N, Nishino I. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1038-44. doi: 10.1136/jnnp-2016-313166. Epub 2016 May 4.</citation>
    <PMID>27147697</PMID>
  </reference>
  <reference>
    <citation>Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, Maisonobe T, Dubourg O, Behin A, Laforet P, Stojkovic T, Eymard B, Costedoat-Chalumeau N, Campana-Salort E, Tournadre A, Musset L, Bader-Meunier B, Kone-Paut I, Sibilia J, Servais L, Fain O, Larroche C, Diot E, Terrier B, De Paz R, Dossier A, Menard D, Morati C, Roux M, Ferrer X, Martinet J, Besnard S, Bellance R, Cacoub P, Arnaud L, Grosbois B, Herson S, Boyer O, Benveniste O; French Myositis Network. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore). 2014 May;93(3):150-7. doi: 10.1097/MD.0000000000000028.</citation>
    <PMID>24797170</PMID>
  </reference>
  <reference>
    <citation>Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients. J Rheumatol. 2017 Sep;44(9):1417. doi: 10.3899/jrheum.160871.C1.</citation>
    <PMID>28864670</PMID>
  </reference>
  <reference>
    <citation>Liang WC, Uruha A, Suzuki S, Murakami N, Takeshita E, Chen WZ, Jong YJ, Endo Y, Komaki H, Fujii T, Kawano Y, Mori-Yoshimura M, Oya Y, Xi J, Zhu W, Zhao C, Watanabe Y, Ikemoto K, Nishikawa A, Hamanaka K, Mitsuhashi S, Suzuki N, Nishino I. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology (Oxford). 2017 Feb;56(2):287-293. doi: 10.1093/rheumatology/kew386. Epub 2016 Nov 6.</citation>
    <PMID>27818386</PMID>
  </reference>
  <reference>
    <citation>Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, Parks CA, Casciola-Rosen L, Christopher-Stine L, Mammen AL. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford). 2017 May 1;56(5):787-794. doi: 10.1093/rheumatology/kew470.</citation>
    <PMID>28096458</PMID>
  </reference>
  <reference>
    <citation>Binns EL, Moraitis E, Maillard S, Tansley S, McHugh N, Jacques TS, Wedderburn LR, Pilkington C, Yasin SA, Nistala K; UK Juvenile Dermatomyositis Research Group (UK and Ireland). Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature. Pediatr Rheumatol Online J. 2017 Oct 31;15(1):77. doi: 10.1186/s12969-017-0205-x. Review.</citation>
    <PMID>29089059</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune necrotizing myopathy</keyword>
  <keyword>anti-HMGCR antibodies</keyword>
  <keyword>anti-SRP antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

